Posted by Michael Wonder on 02 Feb 2023
Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan
2 February 2023 - New results from an early-initiated study show advantages in overall survival.
The antibody-drug conjugate trastuzumab-deruxtecan has been approved since January 2021 for previously treated adults with HER2 positive breast cancer that has metastasized or can no longer be operated on.
